- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05113693
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 in Healthy Volunteers Under Fed Conditions
Objective
- Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Jeonju, Korea, Republic of
- Chonbuk National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy adult volunteers aged 19 ≤ ~ < 55-year-old.
- Weight ≥55kg (man) or 45kg (woman), with calculated body mass index (BMI) of 17.5 ≤ ~ < 30.5 kg/m2.
- Those who have no congenital diseases or chronic diseases within 3 years and have no abnormal symptoms or findings.
- Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and 12-lead ECG results at screening.
- Those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.
- Those who agree to contraception until the 1 month after last administration of clinical trial drugs.
- Those who have the ability and willingness to participate during the entire clinical trail.
Exclusion Criteria:
- Those who have clinically significant disease or medical history of heart failure, Hepatopathy, Type 1 Diabetes, Diabetic ketoacidosis, Edema, Renal dysfunction, galactose intolerance, glucose-galactose malabsorption. And Those who receive intravenous administration of radioactive iodine contrast agents (for intravenous urography, venous cholangiography, angiography, computed tomography using contrast agents, etc.) during clinical trial.
- Those who have past medical history of gastrointestinal disorder (Crohn's disease, ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect the absorption of investigational drug.
Those who have the test results written below
- AST, ALT > 2 times higher than upper normal level
Those who exceeding an alcohol consumption criteria(210g/week) within 6 months before the first administration of investigational drug.
- Beer 1 glass(250ml, Alcohol contents 5%) = 10g
- Soju 1 glass(50ml, Alcohol contents 20%) = 8g
- Wine 1 glass(125ml, Alcohol contents 12%) = 12g
- Those who exceeding smoking criteria(20 cigarettes/day) within 6 months before the first administration of investigational drug.
- Those who received investigational durg by participating in other clinical trial within 6 months before the first administration of investigational drug.
Those who have vital sign written below
- systolic blood pressure ≥140 mmHg or < 90 mmHg
- diastolic blood pressure ≥ 90 mmHg or < 60 mmHg
- Those who have a drug or alcohol abuse history within 1 year before the first administration of investigational drug.
- Those who take barbiturate and related (causing induction or inhibition. of metabolism) drug within 30 days before the first administration of investigational drug.
- Those who received Ethical-the-counter (ETC) drugs or Over-the-counter (OTC) drugs within 10 days before the first administration of investigational drug.
- Those who donated whole blood within 2 months or apheresis within 1 month before the first administration of investigational drug.
- Those who severe acute/chronic medical or mental condition which can increase the safety risk by administration of investigational drug.
- Those who have history of hypersensitivity to active pharmaceutical ingredient or additives.
- Those who are pregnant or breastfeeding.
- Those who can't ingest a high fat diet.
- Those who are deemed inappropriate to participate in clinical trial by investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Period 1 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition. Period 2 - A single dose of 2 tablets(CKD-393 2T) under fed condition. |
QD, PO
QD, PO
|
Experimental: 2
Period 1 - A single dose of 2 tablets(CKD-393 2T) under fed condition. Period 2 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition. |
QD, PO
QD, PO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCt of CKD-501, D759, H053
Time Frame: Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hour
|
AUCt: Area under the concentration-time curve from time zero to time
|
Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hour
|
Cmax of CKD-501, D759, H053
Time Frame: Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hour
|
Cmax: Maximum plasma concentration of the drug
|
Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hour
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Min Gul Kim, M.D, Ph.D., Chonbuk National University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A98_05BE2118
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on CKD-393
-
Chong Kun Dang PharmaceuticalCompletedType II Diabetes MellitusKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
Chong Kun Dang PharmaceuticalCompletedType2DiabetesKorea, Republic of
-
Chong Kun Dang PharmaceuticalUnknownT2DM (Type 2 Diabetes Mellitus)Korea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type 2Korea, Republic of
-
Arvinas Inc.RecruitingRelapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)United States, Spain
-
Chong Kun Dang PharmaceuticalCompletedHealthyKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHypertension | DyslipidemiasKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedAlopeciaKorea, Republic of
-
Chong Kun Dang PharmaceuticalSeoul National University Bundang HospitalCompletedHealthyKorea, Republic of